<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693522</url>
  </required_header>
  <id_info>
    <org_study_id>DW_CTP</org_study_id>
    <nct_id>NCT02693522</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency</brief_title>
  <official_title>Phase III of the Comparative Study on the Efficacy and Safety of Recombinant Somatropin Administered to Patients With Adult Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of recombinant human growth
      hormone on adult growth hormone deficiency
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of fat mass (FM) reduction</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>statistically difference for change from baseline (kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of variation in Lean Body Mass</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>statistically difference for change from baseline (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of variation in Waist to Hip Ratio</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>statistically difference for change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of variation in IGF-1</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>statistically difference for change from baseline (ng/ml)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>somatropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eutropin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>somatropin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eutropin</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Eutropin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 and up

          -  Patients with maximum serum growth hormone concentration of less than 5 ng/ml

          -  Patients who can successfully complete this study based on appropriate medical
             judgment or who expect to benefit from this study

          -  Persons who have agreed in writing to participate in this study

        Exclusion Criteria:

          -  Persons who are currently under treatment after being diagnosed with a malignant tumor

          -  Hepatosis

          -  Renal function disorder

          -  Intra-cranial hypertension

          -  Proliferative diabetic retinopathy

          -  Persons who carry acromegaly activity

          -  Fertile women who are not pregnant or who do not take appropriate contraceptive
             measures and whose urine tested positive for hCG (human Chorionic Gonadotropin)

          -  Mental patients and/or drug addicts and alcoholics

          -  Patients who had participated in the other drug study within the last 30 days prior to
             participating in this study

          -  Patients considered unfit for this study by the attending physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyunghee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

